Shares of Abbott Laboratories (NYSE:ABT) rose in early trading on Friday, after tanking around 6% on Thursday following the company’s first-quarter results.
The company reported its quarterly results largely in line with expectations after including the positive currency impact. Management’s 2026 sales growth outlook reflects a boost from the Exact Sciences acquisition. However, at least one analyst expects “softness in a few segments.”
The Abbott Laboratories Analyst: BTIG analyst Marie Thibault reiterated a Buy rating and price target of $131.
The Abbott Laboratories Thesis: Management held their 2026 sales growth at 6.5%-7.5% despite the boost from the faster-growing Exact Sciences business, Thibault said in the note.
Check out other analyst stock ratings.
The sales growth outlook reflects lower expectations for the Respiratory, CGM, and Structural Heart businesses, she added.
Abbott Laboratories lowered its 2026 projection for adjusted earnings to $5.38-$5.58 per share, which includes …